Global Targeted DNA/RNA Sequencing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Workflow;
Pre-Sequencing, Sequencing, and Data AnalysisBy Type;
DNA-Based Targeted Sequencing and RNA-Based Targeted SequencingBy Application;
Human Biomedical Research, Plant & Animal Sciences, Drug Discovery, and OthersBy End Use;
Academic Research, Hospitals & Clinics, Pharma & Biotech Entities, and OtherBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Targeted DNA/RNA Sequencing Market Overview
Targeted DNA/RNA Sequencing Market (USD Million)
Targeted DNA/RNA Sequencing Market was valued at USD 13,069.87 million in the year 2024. The size of this market is expected to increase to USD 39,366.87 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 17.1%.
Global Targeted DNA/RNA Sequencing Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 17.1 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 17.1 % |
Market Size (2024) | USD 13,069.87 Million |
Market Size (2031) | USD 39,366.87 Million |
Market Concentration | Low |
Report Pages | 368 |
Major Players
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd
- Agilent Technologies
- PierianDx
- Genomatix GmbH
- GATC Biotech Ag
- Oxford Nanopore Technologies
- Macrogen, Inc.
- Thermo Fisher Scientific
- QIAGEN
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Targeted DNA/RNA Sequencing Market
Fragmented - Highly competitive market without dominant players
The targeted DNA/RNA sequencing market is gaining significant traction as the healthcare industry increasingly prioritizes precision-based treatments. These sequencing technologies enable focused genetic analysis, offering a sharper alternative to broader genome-wide approaches. Currently, over 55% of personalized therapeutic strategies incorporate targeted sequencing to guide clinical outcomes, underscoring its essential role in tailored healthcare.
Expanding Role in Diagnostic Applications
The integration of targeted sequencing into clinical diagnostics is rapidly growing due to its sensitivity in detecting disease-specific genetic markers. This technology now supports about 48% of molecular diagnostic procedures, particularly in identifying rare mutations, gene fusions, and other biomarkers essential for early disease detection and treatment planning.
Robust Growth in Research Initiatives
The market is also benefitting from a surge in biomedical research and biomarker exploration, particularly within the biopharmaceutical and academic sectors. Targeted sequencing is currently employed in around 52% of translational research programs, playing a crucial role in discovering novel disease mechanisms and therapeutic pathways.
Streamlined Workflows Through Automation
Automation and bioinformatics integration have further advanced the reliability and scalability of targeted sequencing. Automated platforms now contribute to over 40% of sequencing workflows, offering faster turnaround times and minimizing human error. These improvements are enhancing usability and accelerating adoption across laboratories and healthcare settings.
Targeted DNA/RNA Sequencing Market Recent Developments
-
In June 2024, Bio-Rad introduced the ddSEQ Single-Cell 3' RNA-Seq Kit, designed to facilitate single-cell gene expression research. This cost-effective and rapid kit allows researchers to analyze gene expression at single-cell resolution, potentially advancing studies in oncology, immunology, and more.
-
In May 2024, a paper published in Genomic Medicine emphasized global initiatives aimed at enhancing access to genome sequencing for diagnosing rare genetic disorders. The Medical Genome Initiative advocates for broader insurance coverage, fewer administrative obstacles, and improved clinician education to promote the widespread use of genome sequencing, which could accelerate diagnosis and lower healthcare costs.
Targeted DNA/RNA Sequencing Market Segment Analysis
In this report, the Targeted DNA/RNA Sequencing Market has been segmented by Technology, Workflow, Application, Type, End Use and Geography.
Targeted DNA/RNA Sequencing Market, Segmentation by Workflow
The Targeted DNA/RNA Sequencing Market has been segmented by Workflow into Pre-sequencing, Sequencing and Data Analysis.
Pre-sequencing
Pre-sequencing accounts for approximately 35% of the targeted DNA/RNA sequencing market. This step involves sample preparation, library construction, and target enrichment to ensure high-quality sequencing data. Advancements in automation and workflow optimization are driving growth.
Sequencing
Sequencing represents about 45% of the market. This stage covers the actual generation of sequence data using platforms like next-generation sequencing (NGS). Increased adoption of high-throughput sequencers and cost reduction in sequencing technologies are key drivers.
Data Analysis
Data analysis contributes approximately 20% of the market. This critical phase involves bioinformatics tools and computational platforms to interpret sequencing results. The rising integration of AI-driven analytics and cloud-based solutions supports growth in this segment.
Targeted DNA/RNA Sequencing Market, Segmentation by Type
The Targeted DNA/RNA Sequencing Market has been segmented by Type into DNA Based Targeted Sequencing and RNA Based Targeted Sequencing.
DNA Based Targeted Sequencing
DNA based targeted sequencing accounts for approximately 65% of the market. This approach focuses on specific genomic regions for applications such as cancer genomics, inherited disease screening, and pharmacogenomics. Advancements in target enrichment methods are driving growth in this segment.
RNA Based Targeted Sequencing
RNA based targeted sequencing represents about 35% of the market. This technique allows for the identification of gene expression profiles and fusion transcripts in research and clinical applications. The increasing demand for transcriptome profiling and liquid biopsy is boosting market expansion.
Targeted DNA/RNA Sequencing Market, Segmentation by Application
The Targeted DNA/RNA Sequencing Market has been segmented by Application into Human Biomedical Research, Plant & Animal Sciences, Drug Discovery and Others.
Human Biomedical Research
Human biomedical research accounts for approximately 50% of the targeted DNA/RNA sequencing market. This segment is driven by clinical applications such as cancer genomics, genetic disease research, and personalized medicine. Increasing adoption of next-generation sequencing technologies supports growth.
Plant & Animal Sciences
Plant and animal sciences represent about 20% of the market. Targeted sequencing helps in crop improvement, breeding programs, and veterinary genomics. Growing focus on food security and sustainable agriculture drives this segment’s expansion.
Drug Discovery
Drug discovery contributes approximately 20% of the market. This application utilizes targeted sequencing to identify biomarkers, evaluate drug responses, and optimize clinical trial design. The rising demand for precision therapeutics fuels this segment.
Others
Others account for around 10% of the market, including applications in forensics, microbial genomics, and environmental monitoring. Advancements in sequencing workflows and bioinformatics tools support growth in this diverse segment.
Targeted DNA/RNA Sequencing Market, Segmentation by End Use
The Targeted DNA/RNA Sequencing Market has been segmented by End Use into Academic Research, Hospitals & Clinics, Pharma & Biotech Entities and Other.
Academic Research
Academic research accounts for approximately 40% of the targeted DNA/RNA sequencing market. This segment benefits from rising funding for genomics and biomedical research. The increasing use of sequencing technologies in universities and research institutions drives growth.
Hospitals & Clinics
Hospitals and clinics represent about 30% of the market. These end users adopt targeted sequencing for diagnostics, personalized medicine, and oncology applications. Growing focus on precision healthcare and integrated sequencing platforms supports expansion.
Pharma & Biotech Entities
Pharma and biotech entities contribute around 20% of the market. They leverage targeted sequencing for drug discovery, clinical trials, and biomarker validation. Increasing collaboration between biotech firms and academic institutions is boosting this segment.
Other
The 'Other' category holds about 10% of the market, including applications in forensic science, veterinary research, and environmental genomics. Technological advancements in sequencing solutions and bioinformatics integration drive growth.
Targeted DNA/RNA Sequencing Market, Segmentation by Geography
In this report, the Targeted DNA/RNA Sequencing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Targeted DNA/RNA Sequencing Market Share (%), by Geographical Region
North America
North America holds approximately 40% of the targeted DNA/RNA sequencing market, driven by strong R&D investments, advanced biotech infrastructure, and high adoption of next-generation sequencing technologies. The presence of leading genomics companies further supports growth.
Europe
Europe accounts for around 30% of the market, supported by robust biomedical research programs and favorable regulatory policies. Increasing collaboration between academia and biopharma firms enhances the regional market.
Asia Pacific
Asia Pacific contributes about 20% of the market, driven by rising healthcare investments and expansion of genomic research initiatives. Countries such as China and India play a pivotal role in regional growth.
Middle East and Africa
Middle East and Africa hold around 5% of the market. Increased government focus on genomic medicine and the development of biotech hubs contribute to the growing demand for targeted sequencing solutions.
Latin America
Latin America represents approximately 5% of the market, led by countries like Brazil and Mexico. Rising investments in genomic research and increasing healthcare awareness support market growth.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Targeted DNA/RNA Sequencing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
---|---|---|---|---|---|
Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Targeted SSI prevention strategies emerging
- Tailored care plans improve outcomes
-
Better microbial profiling with new tech - The ability to achieve better microbial profiling with new technologies is a key driver for the global targeted DNA/RNA sequencing market. Innovations in sequencing platforms, such as next-generation sequencing (NGS), microfluidics, and enhanced library preparation kits, have significantly improved the sensitivity and specificity of detecting diverse microbial communities. These advancements enable researchers and clinicians to perform precise, high-throughput analysis of microbial genomes, even at low abundance, leading to better understanding of infections, resistance patterns, and host-microbe interactions.
Accurate microbial profiling is essential for applications in infectious disease diagnostics, personalized medicine, epidemiology, and environmental microbiology. New technologies allow for rapid identification of pathogens, antibiotic resistance genes, and microbial biomarkers, supporting targeted treatments and outbreak control. As the demand for precision microbiome analysis grows across research and clinical settings, the adoption of targeted DNA/RNA sequencing platforms is expected to accelerate, driving strong market growth.
Restraints
- High Initial Investment Costs
- Complex Data Analysis and Interpretation
- Data Privacy and Security Concerns
-
Regulatory Challenges and Compliance Requirements - Regulatory challenges and compliance requirements present a significant restraint on the global targeted DNA/RNA sequencing market. Sequencing technologies used in clinical and diagnostic settings must adhere to stringent regulations concerning data accuracy, validation procedures, and patient safety. Gaining approval from agencies such as the FDA, EMA, or equivalent regulatory bodies can be time-consuming and costly, particularly when introducing new platforms or updating existing protocols for clinical use.
Additionally, compliance with data privacy laws, quality assurance standards, and laboratory certifications adds operational complexity for sequencing providers. The need to navigate different regional and national regulatory frameworks can delay market entry and hinder international expansion. These challenges are particularly burdensome for startups and smaller labs that lack dedicated regulatory teams, limiting innovation and reducing the pace of commercial adoption in some segments of the market.
Opportunities
- Expansion of Precision Medicine Initiatives
- Integration of Genomic Data into Clinical Practice
- Development of Companion Diagnostics
-
Adoption of Liquid Biopsies for Non-invasive Testing - The increasing adoption of liquid biopsies for non-invasive testing is creating major opportunities for the global targeted DNA/RNA sequencing market. Liquid biopsies allow for the detection of circulating tumor DNA (ctDNA), cell-free RNA, and other biomarkers from blood samples, offering a less invasive, repeatable alternative to tissue biopsies. Targeted sequencing plays a vital role by providing the sensitivity and precision needed to identify genetic mutations and expression profiles that guide diagnosis and treatment.
This approach is gaining traction in oncology, prenatal testing, and chronic disease monitoring, where early detection and real-time insights are critical. As healthcare systems move toward precision medicine and personalized care, the combination of liquid biopsy and targeted sequencing enables faster, more accurate clinical decisions. The growing use of this technology in clinical practice and research is expected to drive sustained market expansion globally.
Competitive Landscape Analysis
Key players in Global Targeted DNA/RNA Sequencing Market include;
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd
- Agilent Technologies
- PierianDx
- Genomatix GmbH
- GATC Biotech Ag
- Oxford Nanopore Technologies
- Macrogen, Inc.
- Thermo Fisher Scientific
- QIAGEN
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Workflow
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Targeted DNA/RNA Sequencing Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Targeted SSI prevention strategies emerging
-
Tailored care plans improve outcomes
-
Better microbial profiling with new tech
-
- Restraints
- High Initial Investment Costs
- Complex Data Analysis and Interpretation
- Data Privacy and Security Concerns
- Regulatory Challenges and Compliance Requirements
- Opportunities
- Expansion of Precision Medicine Initiatives
- Integration of Genomic Data into Clinical Practice
- Development of Companion Diagnostics
- Adoption of Liquid Biopsies for Non-invasive Testing
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Targeted DNA/RNA Sequencing Market, By Workflow, 2021 - 2031 (USD Million)
- Pre-sequencing
- Sequencing
- Data Analysis
- Targeted DNA/RNA Sequencing Market, By Type, 2021 - 2031 (USD Million)
- DNA Based Targeted Sequencing
- RNA Based Targeted Sequencing
- Targeted DNA/RNA Sequencing Market, By Application, 2021 - 2031 (USD Million)
- Human Biomedical Research
- Plant & Animal Sciences
- Drug Discovery
- Others
- Targeted DNA/RNA Sequencing Market, By End Use, 2021 - 2031 (USD Million)
- Academic Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Other
- Targeted DNA/RNA Sequencing Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Targeted DNA/RNA Sequencing Market, By Workflow, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd
- Agilent Technologies
- PierianDx
- Genomatix GmbH
- GATC Biotech Ag
- Oxford Nanopore Technologies
- Macrogen, Inc.
- Thermo Fisher Scientific
- QIAGEN
- Company Profiles
- Analyst Views
- Future Outlook of the Market